Back to Top
Go Back
Journal Photo for Leukemia & Lymphoma
Peer reviewed only Open Access

Leukemia & Lymphoma (L&L)

Publisher : Taylor & Francis
Leukemia & Lymphoma disease biology ethics and epidemiology
Claim Your Journal Get PRC Visit Website
e-ISSN 1029-2403
p-ISSN 1042-8194
Issue Frequency Monthly
Impact Factor 2.2
Est. Year 1989
Mobile 4402080520500
DOI YES
Language English
APC YES
Impact Factor Assignee GOOGLE SCHOLAR
Email apol@cc.huji.ac.il

Journal Descriptions

Leukemia & Lymphoma is an international peer reviewed journal that publishes research on all aspects of hematological malignancies. The journal aims to address the needs of physicians and scientists interested in clinical, translational, laboratory and basic science research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders. Leukemia & Lymphoma covers from clinical and clinico-pathological investigations to fundamental research in the following topics: disease biology mechanisms of action of novel agents development of combination chemotherapy pharmacology and pharmacogenomics ethics and epidemiology

Leukemia & Lymphoma (L&L) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Leukemia & Lymphoma, disease biology, ethics and epidemiology, pharmacology and pharmacogenomics, mechanisms of action of novel agents, unique clinical observations, review articles, letters to the editor , Online or Print , Monthly Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1042-8194, E-ISSN: 1029-2403, Established: 1989, Impact Factor: 2.2
  • Provides Crossref DOI

  • Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE

Indexing

Publications of L&L

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia
Karima Amaador October, 2022
Waldenström’s Macroglobulinemia (WM) is a rare type of indolent non-Hodgkin lymphoma (NHL) that remains incurable. Several effective agents such as monoclonal antibodies (in combination w...
From mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma
Aaron Seth October, 2022
Glucocorticoids, including dexamethasone, have been a mainstay of treatment for multiple myeloma (MM) for decades. In current treatment protocols and NCCN clinical practice guidelines, dexam...
Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data
Cecilie E November, 2022
The aims of this study are to describe health-related quality of life (HRQoL, SF-36) and fatigue in long-term indolent lymphoma survivors, compared to normative data, and to examine factors ...
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands
Geneviève I November, 2022
Suboptimal guideline adherence in chronic myeloid leukemia (CML) care is associated with worse treatment outcomes. Current study focused on adherence to seven quality indicators (QIs) based ...
Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the...
Christopher Kim November, 2022
This study evaluated prognostic performance of International Staging System (ISS), revised ISS, and chromosomal abnormalities (CA) in newly diagnosed multiple myeloma patients to describe tr...
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
Philippe Armand November, 2022
The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hema...
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-...
Stephen Lim November, 2022
Chimeric antigen receptor T-cell (CAR-T) infusion settings may impact healthcare resource use (HRU) and reimbursement amounts. Adults with diffuse large B-cell lymphoma receiving CAR-T thera...
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record data...
Christopher Okigbo November, 2022
Patients with relapsed/refractory multiple myeloma (RRMM) resistant to multiple drug classes remain a high unmet need population. This longitudinal retrospective cohort study assessed real-w...
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a ...
Stephen Opat November, 2022
Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malig...
Bilal Tariq December, 2022
BTK inhibitor exposure increases significantly when coadministered with CYP3A inhibitors, which may lead to dose-related toxicities. This study explored the pharmacokinetics, efficacy, and s...